Translate page


Susan BranfordAgnes YONG w labcoat1  




Session 2: CML management, Practicalities
Chair: Prof. Tim Hughes

  • Molecular monitoring in CML
    (A/Prof Susan Branford)
  • Allograft - still a role in CML?
    (A/Prof Agnes Yong)



Susan Branford  

Molecular monitoring in CML
A/Prof. Susan Branford - SA Pathology / Universities of Adelaide and South Australia

  • Gold standards of monitoring CML
  • Molecular monitoring for best patient outcomes
  • Milestone molecular responses in the first 12 months
  • Long-term molecular monitoring recommended for prediction of resistance
  • Imatinib resistant BCR-ABL1 kinase domain mutations
  • When to test for mutations
  • Long-term molecular monitoring of responding patients important to monitor adherence
  • Regular molecular monitoring recommended for optimal disease management
  • Summary
  • Q&A Session

Agnes YONG w labcoat1


Allograft - still a role in CML?

A/Prof. Agnes Yong - SAHMRI / University of Adelaide

  • Allogeneic stem cell transplantation: the most successful immunotherapy in CML
  • Survival after alloSCT
  • EBMT score for alloSCT in CML
  • Which CML patient needs transplant?
  • AlloSCT for patients harboring T315I BCR-ABL mutated leukemias
  • Clinical impact of pretransplant use of multiple TKI's on the outcome of alloSCT
  • Economics and alloSCT in CML
  • Outcomes of alloSCT in children and adolescents
  • Which conditioning regime for alloSCT?
  • Role of TKI's after transplant
  • Long-term follow-up after transplant for CML
  • Summary
  • Q&A Session